ORCID Profile
0000-0001-7022-8332
Current Organisations
Johns Hopkins University
,
Duquesne University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Public Library of Science (PLoS)
Date: 24-08-2018
Publisher: American Association for the Advancement of Science (AAAS)
Date: 05-07-2017
DOI: 10.1126/SCITRANSLMED.AAG0426
Abstract: Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.
Publisher: Elsevier BV
Date: 06-2016
Publisher: Elsevier BV
Date: 12-2013
Publisher: Public Library of Science (PLoS)
Date: 04-03-2020
Publisher: American Association for the Advancement of Science (AAAS)
Date: 22-06-2018
Abstract: It has been 20 years since the first derivation of human embryonic stem cells. That milestone marked the start of a scientific and public fascination with stem cells, not just for their biological properties but also for their potentially transformative medical uses. The next two decades of stem cell research animated an array of bioethical debates, from the destruction of embryos to derive stem cells to the creation of human-animal hybrids. Ethical tensions related to stem cell clinical translation and regulatory policy are now center stage and a topic of global discussion this week at the International Society for Stem Cell Research (ISSCR) annual meeting in Melbourne, Australia. Care must be taken to ensure that entry of stem cell–based products into the medical marketplace does not come at too high a human or monetary price.
Publisher: Wiley
Date: 31-05-2013
DOI: 10.1111/DEWB.12032
Publisher: Springer Science and Business Media LLC
Date: 12-2021
DOI: 10.1038/S41591-021-01590-5
Abstract: Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years.
Publisher: Elsevier BV
Date: 2016
Publisher: Elsevier BV
Date: 11-2018
Publisher: Elsevier BV
Date: 12-2008
DOI: 10.1016/J.STEM.2008.11.009
Abstract: The International Society for Stem Cell Research (ISSCR) task force that developed new Guidelines for the Clinical Translation of Stem Cells discusses core principles that should guide the responsible transition of basic stem cell research into appropriate clinical applications.
Publisher: Public Library of Science (PLoS)
Date: 25-03-2008
Publisher: The Company of Biologists
Date: 15-03-2017
DOI: 10.1242/DEV.140111
Abstract: Research involving human organoids and gastruloids involves ethical issues associated with their derivation as well as their current and future uses. These include unique issues related to the extent of maturation that can be achieved in vitro or through chimeric research, as well as fundamental ethical considerations such as those concerning the provenance of human biomaterials and the use of gene-editing technologies. Many of these issues are not specifically addressed by existing ethics oversight mechanisms, but these mechanisms might be easily extended to help ensure that human organoid and related research moves forward in an ethically appropriate manner.
No related grants have been discovered for Jeremy Sugarman.